Md Rakibul Islam Masud, Md. Nizamul Haque, M. Khan, Badrun Nahar Tuly, Md Golam Zel Asmaul Husna, S. Alam
{"title":"肺癌上腔静脉综合征姑息放疗5段20 Gy与10段30 Gy的比较","authors":"Md Rakibul Islam Masud, Md. Nizamul Haque, M. Khan, Badrun Nahar Tuly, Md Golam Zel Asmaul Husna, S. Alam","doi":"10.3329/cbmj.v12i1.64284","DOIUrl":null,"url":null,"abstract":"A quasi-experimental study was conducted to compare palliative radiotherapy between 20 Gy in 5 fractions and 30 Gy in 10 fractions in superior vena cava syndrome due to carcinoma of lung. This study was done in National Institute of Cancer Research and Hospital (NICRH), Dhaka, Bangladesh, from September 2017 to August 2018. A total of 60 patients were enrolled in the study – 30 in each group. In Arm A, patients received 20 Gy in 5 fractions in 1 week, while in Arm B, patients received 30 Gy in 10 fractions in 2 weeks. Every patient was evaluated routinely to see the treatment outcome and toxicities. The mean age of Arm-A was 57.53±5.5 years and that of Arm-B was 57.40±5.4 years. After treatment, improvement of symptoms (e.g., edema, venous distension, dyspnea) of SVCS was observed. After 1 month of radiotherapy, complete resolution of venous distension occurred in majority of the patients (73.3% vs. 80%) and partial resolution occurred in rest of them (26.7% vs. 20%) in arms A and B respectively. Most of patients showed complete resolution of edema (83.3% vs. 86.7%), while few had partial resolution (16.7% vs. 13.3%) in arms A and B respectively. Symptoms of SVCS did not recur in any of the patients of both arms. Performance status also improved in all patients. Assessment of tumor response at the last follow-up showed partial response in 66.7% patients of Arm-A and 73.3% patients of Arm-B. Stable disease was observed in 33.3% patients of Arm-A and 26.7% patients of Arm-B. None of the patients showed disease progression. Toxicities included dysphagia (26.7% vs. 33.33%), fatigue (23.33% vs. 20%), nausea and vomiting (16.67% vs. 20%) and skin reaction (16.67% vs. 13.33%) in Arm-A and Arm-B respectively. All of those toxicities were grade-1 and easily controlled. There was no statistically significant difference between two treatment groups in terms of palliation of symptoms of SVCS, tumor response and toxicities. To summarize, although tumor response was not much satisfactory, both 20 Gy in 5 fractions and 30 Gy in 10 fractions are equally effective radiotherapy regimens in palliation of symptoms of SVCS due to lung cancer with tolerable toxicities. Hence, 20 Gy in 5 fractions can be a reasonable treatment choice in a resource-poor country like Bangladesh. \nCBMJ 2023 January: Vol. 12 No. 01 P: 33-40","PeriodicalId":10576,"journal":{"name":"Community Based Medical Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Comparison of Palliative Radiotherapy Between 20 Gy in 5 Fractions and 30 Gy in 10 Fractions in Superior Vena Cava Syndrome Due to Carcinoma of Lung\",\"authors\":\"Md Rakibul Islam Masud, Md. Nizamul Haque, M. Khan, Badrun Nahar Tuly, Md Golam Zel Asmaul Husna, S. Alam\",\"doi\":\"10.3329/cbmj.v12i1.64284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A quasi-experimental study was conducted to compare palliative radiotherapy between 20 Gy in 5 fractions and 30 Gy in 10 fractions in superior vena cava syndrome due to carcinoma of lung. This study was done in National Institute of Cancer Research and Hospital (NICRH), Dhaka, Bangladesh, from September 2017 to August 2018. A total of 60 patients were enrolled in the study – 30 in each group. In Arm A, patients received 20 Gy in 5 fractions in 1 week, while in Arm B, patients received 30 Gy in 10 fractions in 2 weeks. Every patient was evaluated routinely to see the treatment outcome and toxicities. The mean age of Arm-A was 57.53±5.5 years and that of Arm-B was 57.40±5.4 years. After treatment, improvement of symptoms (e.g., edema, venous distension, dyspnea) of SVCS was observed. After 1 month of radiotherapy, complete resolution of venous distension occurred in majority of the patients (73.3% vs. 80%) and partial resolution occurred in rest of them (26.7% vs. 20%) in arms A and B respectively. Most of patients showed complete resolution of edema (83.3% vs. 86.7%), while few had partial resolution (16.7% vs. 13.3%) in arms A and B respectively. Symptoms of SVCS did not recur in any of the patients of both arms. Performance status also improved in all patients. Assessment of tumor response at the last follow-up showed partial response in 66.7% patients of Arm-A and 73.3% patients of Arm-B. Stable disease was observed in 33.3% patients of Arm-A and 26.7% patients of Arm-B. None of the patients showed disease progression. Toxicities included dysphagia (26.7% vs. 33.33%), fatigue (23.33% vs. 20%), nausea and vomiting (16.67% vs. 20%) and skin reaction (16.67% vs. 13.33%) in Arm-A and Arm-B respectively. All of those toxicities were grade-1 and easily controlled. There was no statistically significant difference between two treatment groups in terms of palliation of symptoms of SVCS, tumor response and toxicities. To summarize, although tumor response was not much satisfactory, both 20 Gy in 5 fractions and 30 Gy in 10 fractions are equally effective radiotherapy regimens in palliation of symptoms of SVCS due to lung cancer with tolerable toxicities. Hence, 20 Gy in 5 fractions can be a reasonable treatment choice in a resource-poor country like Bangladesh. \\nCBMJ 2023 January: Vol. 12 No. 01 P: 33-40\",\"PeriodicalId\":10576,\"journal\":{\"name\":\"Community Based Medical Journal\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Community Based Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3329/cbmj.v12i1.64284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Community Based Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/cbmj.v12i1.64284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
采用准实验方法比较20 Gy分5段和30 Gy分10段姑息放疗对肺癌上腔静脉综合征的治疗效果。该研究于2017年9月至2018年8月在孟加拉国达卡的国家癌症研究所和医院(NICRH)完成。共有60名患者参加了这项研究,每组30名。在A组中,患者在1周内接受5次20 Gy的治疗,而在B组中,患者在2周内接受10次30 Gy的治疗。对每位患者进行常规评估,以了解治疗结果和毒性。a组平均年龄57.53±5.5岁,b组平均年龄57.40±5.4岁。治疗后,观察到SVCS症状(水肿、静脉扩张、呼吸困难)改善。放疗1个月后,A组和B组绝大多数患者静脉扩张完全消退(73.3% vs. 80%),其余患者静脉扩张部分消退(26.7% vs. 20%)。在A组和B组中,大多数患者水肿完全消退(83.3% vs. 86.7%),少数患者部分消退(16.7% vs. 13.3%)。两组患者均未出现SVCS症状复发。所有患者的运动状态均有改善。最后一次随访时肿瘤反应评估显示,a组66.7%患者部分缓解,b组73.3%患者部分缓解。a组33.3%的患者病情稳定,b组26.7%。所有患者均未出现疾病进展。a臂和b臂的毒性分别为吞咽困难(26.7%对33.33%)、疲劳(23.33%对20%)、恶心和呕吐(16.67%对20%)和皮肤反应(16.67%对13.33%)。所有这些毒性均为1级,易于控制。两个治疗组在SVCS的症状缓解、肿瘤反应和毒性方面无统计学差异。综上所述,尽管肿瘤反应不太令人满意,但在缓解毒性可耐受的肺癌引起的SVCS症状方面,5分20 Gy和10分30 Gy都是同样有效的放疗方案。因此,在孟加拉国这样资源贫乏的国家,5份20戈瑞可能是一种合理的治疗选择。中华医学杂志2023 1月12期01期33-40页
A Comparison of Palliative Radiotherapy Between 20 Gy in 5 Fractions and 30 Gy in 10 Fractions in Superior Vena Cava Syndrome Due to Carcinoma of Lung
A quasi-experimental study was conducted to compare palliative radiotherapy between 20 Gy in 5 fractions and 30 Gy in 10 fractions in superior vena cava syndrome due to carcinoma of lung. This study was done in National Institute of Cancer Research and Hospital (NICRH), Dhaka, Bangladesh, from September 2017 to August 2018. A total of 60 patients were enrolled in the study – 30 in each group. In Arm A, patients received 20 Gy in 5 fractions in 1 week, while in Arm B, patients received 30 Gy in 10 fractions in 2 weeks. Every patient was evaluated routinely to see the treatment outcome and toxicities. The mean age of Arm-A was 57.53±5.5 years and that of Arm-B was 57.40±5.4 years. After treatment, improvement of symptoms (e.g., edema, venous distension, dyspnea) of SVCS was observed. After 1 month of radiotherapy, complete resolution of venous distension occurred in majority of the patients (73.3% vs. 80%) and partial resolution occurred in rest of them (26.7% vs. 20%) in arms A and B respectively. Most of patients showed complete resolution of edema (83.3% vs. 86.7%), while few had partial resolution (16.7% vs. 13.3%) in arms A and B respectively. Symptoms of SVCS did not recur in any of the patients of both arms. Performance status also improved in all patients. Assessment of tumor response at the last follow-up showed partial response in 66.7% patients of Arm-A and 73.3% patients of Arm-B. Stable disease was observed in 33.3% patients of Arm-A and 26.7% patients of Arm-B. None of the patients showed disease progression. Toxicities included dysphagia (26.7% vs. 33.33%), fatigue (23.33% vs. 20%), nausea and vomiting (16.67% vs. 20%) and skin reaction (16.67% vs. 13.33%) in Arm-A and Arm-B respectively. All of those toxicities were grade-1 and easily controlled. There was no statistically significant difference between two treatment groups in terms of palliation of symptoms of SVCS, tumor response and toxicities. To summarize, although tumor response was not much satisfactory, both 20 Gy in 5 fractions and 30 Gy in 10 fractions are equally effective radiotherapy regimens in palliation of symptoms of SVCS due to lung cancer with tolerable toxicities. Hence, 20 Gy in 5 fractions can be a reasonable treatment choice in a resource-poor country like Bangladesh.
CBMJ 2023 January: Vol. 12 No. 01 P: 33-40